Objective: We studied the individual course of interferon gamma producing blood lymphocyte count (IFGC) of 15 multiple sclerosis patients started on 8 MIU beta interferon administered subcutaneously each other day. Methods: Mononuclear blood cells were prepared before treatment and on day 3, 9, 15, as well as after month 1, 2, 3 and 4 of therapy. After stimulation intracellular interferon gamma was detected with monoclonal fluorescent antibodies and measured by flowcytometry. IFGC is given as percentage of all gated lymphocytes. Results: forty-eight hours after first interferon beta application the mean IFGC dropped significantly from 11.37 to 7.09 (P<0.05) and to 4.22 within 4 months. Whereas the majority of patients showed a decrease of IFGC from the beginning of therapy, in three of the 15 patients a transient increase of IFGC was seen suggesting a different response to immunomodulatory therapy. Conclusions: Interferon gamma producing lymphocyte count might be a useful tool to determine the biological effect of interferon β therapy in multiple sclerosis patients.
Huber M., Bamborschke S., Assheuer J., HeiB WD (1988) Intravenous natural beta interferon treatment of chronic exacerbating-remitting multiple sclerosis: clinical response and MRI/CSF findings. J Neurol235: 171-173.
2.
Arnason BG (1993) Interferon beta in multiple sclerosis. Neurology43: 641-643.
3.
Jacobs L., Johnson KP (1994) A brief history of the use of interferons as treatment of multiple sclerosis. Arch Neurol51: 1245-1252.
4.
Paty DW, Li DKB the UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group. ( 1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. Neurology43: 662-667.
5.
The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/ MRI Analysis Group. (1995) Interferon beta-1b in the treatment of multiple sclerosis: Final outcome of the randomized controlled trial. Neurology45: 1277-1285.
6.
Jacobs LD et al. (1996) Intramuscular Interferon Beta-1a for Disease Progression in Relapsing Multiple Sclerosis. Ann Neurol39: 285 - 294.
7.
Knobler RL et al. (1993) Systemic recombinant human interferon-beta treatment of relapsing-remitting multiple sclerosis: pilot study analysis and six-years follow-up. J Interferon Res13: 333 - 340.
8.
Sadiq SA, Revesz KJ, Lassmann AB, Miller JR (1996) Antibodies to interferon-β in patients with multiple sclerosis: detection and clinical effect. Neurology46: A136.
9.
Goldstein D. et al. (1989) Human biologic response modification by interferon in the absence of measurable serum concentrations: a comparative trial of subcutaneous and intravenous interferon-β serine . J Natl Cancer Inst81: 1061-1068.
10.
Khan OA et al. (1996) Interferon beta-1b serum levels in multiple sclerosis patients following subcutaneous administration. Neurology46: 1639-1643.
11.
Hirsch LR, Panitch HS, Johnson KP (1985) Lymphocytes from Multiple Sclerosis Patients Produce Elevated Levels of Gamma Interferon in Vitro. J Clin Immunol5: 386-389.
12.
Lu CZ, Jensen MA, Arnason Bgw. (1993) Interferon gamma- and interleukin-4-secreting cells in multiple sclerosis. J Neuroimmunol46: 123-128.
13.
Olsson T. (1992) Cytokines in neuroinflammatory disease: role of myelinautoreactive T cell production of interferon-gamma. J Neuroimmunol40: 211- 218.
14.
Link J. (1994) Interferon-gamma, interleukin-4 and transforming growth factor-beta mRNA expression in multiple sclerosis and myasthenia gravis . Acta Neurol Scand (Suppl)158: 1- 58.
15.
Olsson T. (1995) Cytokine-producing cells in experimental autoimmune encephalomyelitis and multiple sclerosis. Neurology45: 11-15.
16.
Panitch HS (1992) Interferons in Multiple Sclerosis. A review of the evidence. Drugs44: 946-962.
17.
Noronha A., Toscas A., Jensen MA (1993) Interferon beta decreases T cell activation and interferon gamma production in multiple sclerosis. J Neuroimmunol46: 145-154.
18.
Fierlbeck G. et al. (1994) Neutralizing interferon beta antibodies in melanoma patients treated with recombinant and natural interferon beta. Cancer Immunology, Immunotherapy39: 263 - 268.
19.
Larocca AP et al. (1989) Evaluation of neutralizing antibodies in patients with recombinant interferon-beta(ser). J Interferon Res9: (Suppl) 51-60.
20.
Pestka S. (1981) Assay of interferons. Methods in enzymology78: 339-414.
21.
Lengyel P. (1981) Mechanisms of Interferon Action: The (2'-5')(A)n Synthetase-RNase L Pathway. Interferon3: 78-99.
22.
Horisberger MA, Hochkeppel HK (1987) IFN-alpha induced human 78 kD protein: purification and homologies with the mouse Mx protein, production of monoclonal antibodies and potentiation effect of IFN-gamma. J Interferon Res7: 331-343.
23.
Liberati AM et al. (1994) Double blind randomized phase I study on the clinical tolerance and pharmacodynamics of natural and recombinant interferon-β given intravenously. J Interferon Res14: 61- 69.
24.
Witt PL et al. (1993) Pharmacodynamics of biological response in vivo after single and multiple doses of interferon-beta. J Immunother13: 191-200.
25.
Liberati AM et al. (1992) Double-blind randomized phase I study on the clinical tolerance and biological effects of natural and recombinant interferon-beta. J Interferon Res12: 329-336.
26.
Towbin H., Jakschies D., Von Wussow P., Horisberger MA (1992) A whole blood immunoassay for interferon-inducible human Mx protein. J Interferon Res12: 67-74.
27.
Meyer KC et al. (1992) Effects of interferon beta or gamma on neopterin biosynthesis and tryptophan degradation by human alveolar macrophages in vitro: synergy with lipopolysaccharide. Am J Respir Cell Mol Biol6: 639-646.
28.
Huber C. et al. (1984) Immune response-associated production of neopterin. J Exp Med160: 310-316.
29.
Oh SK et al. (1994) Quantitation of interferon-induced Mx protein in whole blood lysates by an immunochemiluminescent assay: elimination of protease activity of cell lysates in toto. J Immunol Meth176: 79-91.
30.
Dayal AS, Jensen MA, Lledo A., Arnason Bgw. (1995) Interferon-gamma-secreting cells in multiple sclerosis patients treated with interferon beta-1b. Neurology45: 2173-2177.
31.
Katayama K. et al. (1993) Alpha interferon enhances gamma interferon production of peripheral blood mononuclear cells pre-activated with phytohemagglutinin. Gastroenterol Jpn28: 673-678.
32.
Chattenoud L. et al. (1991) Corticosteroids inhibition of the OKT3-induced cytokine-related syndrome - dosage and kinetics prerequisites. Transplantation51: 334-338.
33.
Ellaurie M. , Yost SL, Rosenstreich DL (1991) A simplified human whole blood essay for dust mite-specific gamma interferon production in vitro. Ann Allergy66: 143 -147.
34.
Isobe T., Lillehoj HS (1992) Effects of corticosteroids on lymphocyte subpopulations and lymphokine secretion in chickens. Avian Dis36: 590-596.
